Successful Treatment of Critical Coronavirus Disease 2019 in a Patient with Lung Cancer Concomitant with Pembrolizumab‐induced Arthritis by Methylprednisolone, Baricitinib, and Remdesivir

Naohiro Oda,Keiji Miyoshi,Daisuke Morichika,Yuka Beika,Takahiro Taki,Reo Mitani,Toshiaki Okada,Ichiro Takata

Clinical case reports（2021）

引用 0|浏览0

暂无评分

摘要

COVID-19 in cancer patients on immunosuppressive agents for the treatment of immune-related adverse events of immune checkpoint inhibitors can rapidly deteriorate. The combination therapy with methylprednisolone, baricitinib, and remdesivir may be effective for critical COVID-19, and further clinical trials are warranted.

查看译文

关键词

baricitinib,COVID-19,immune checkpoint inhibitor,immune-related adverse event,lung cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要